Galderma Group AG

Galderma’s Sculptra gains EU MDR approval, expanding into new body areas and boosting investor confidence with a S&P BBB rating upgrade, positioning it for growth in the booming aesthetics market.

Galderma Group AG reported record first quarter net sales of $1.129 billion, exceeding expectations and solidifying its position as a leader in the dermatology category.

Galderma Group AG exceeded expectations with a 5.4% increase in sales for the first quarter of 2025, driven by strong product demand and new launches, including the “Scratch Resistance” campaign for NEMLUVIO.